Home

Pelago Bioscience enable successful Drug Discovery by providing physiologically relevant high quality Target Engagement data using the patented CETSA® method. We combine extensive commercial Drug Discovery experience with world leading fundamental basic scientific research.

Our focus is to deliver high quality target engagement data to our customers and partners, enabling faster development of better and more efficacious new drugs. By outsourcing your Target Engagement assays to us you reduce your risk and speed up project progression. We provide a flexible fee for service model and can also offer method sublicensing, tech transfer as well as consulting and risk shared collaborations.

 

Meet Us


Stockholm September 14-15

NLSDays is the largest Life Science Invest and Partnering meeting in the Nordic region. Read more here


Los Angeles September 19-20

Marcus Evans summit in Los Angeles.

Liverpool October 13-14

ELRIG celebrates its 10th Anniversary of its flagship event, Drug Discovery, which will this year take place at ACC in Liverpool, UK, located in the heart of the city beside the historic Albert Docks, from 13th-14th October 2016. Read more

 

Latest Posts

     

August 2016:

WuXi collaboration


Pelago Bioscience now contributes CETSA® measurements to the service portfolio of WuXi AppTec. Read the full press release here: wuxi and pelago.pdf

July 2016:

Sales and Business Manager at Pelago


Read about the position and how to apply here in the advert: salesandbdperson.pdf

May 2016:

CETSA® and Pelago explained in 8 minutes


April 2016:

New publication on CETSA® HT


Pelagos CSO Daniel Martinez Molina and Pär Nordlund co-authors the very first paper on CETSA® HT screening, identifying novel binders of Thymidilate Synthase. You will find the publication here.

March 2016:

CETSA rules!
 


The CETSA® method is becoming a standard technique, it is being used routinely to demonstrate target engagement of small molecule's for a specific target in the living cell. Read the review in GEN Exclusives update.

December 2015:

Min Stora Dag
 


This year we are very proud and happy to donate our christmas gift to Min Stora Dag/My Special Day - a foundation who give special kids great memories. Merry Christmas!

November 2015:

Astra Zeneca collaboration


Our new strategic collaboration with AstraZeneca will further accelerate the development of CETSA® applications relevant for drug discovery. pressreleasepelagoaz.pdf

November 2015:

SWELife/Vinnova Grant


We have together with Karolinska Universitetssjukhuset been awarded a SWELife/Vinnova grant to start exploring CETSA® as an In Vitro Diagnostic tool in the validation of predictive biomarkers. swelifegrantpressrelease.pdf

October 2015:

Pfizer sub-licensing agreement


Pfizer Inc. and Pelago annouce that we have entered in to a sub-licensing agreement on the use of the CETSA™ method. Read the full statement here: pressreleasepbpfizer.pdf

 

September 2015:

Pelago enters a collaboration with Biovica


Pelago and Biovica announce our collaboration to develop a novel platform to enable development of new oncology drugs. Read more from the pressrelease